The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [14C]-BI 425809 in Healthy Males-Reference-Cited by-同舟云学术

The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [14C]-BI 425809 in Healthy Males

Published:2021-12-22 Issue:1 Volume:42 Page:87-99
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Burkard Ute^ORCID,Desch Michael,Shatillo Yury,Wunderlich Glen,Mack Salome Rebecca,Schlecker Christina,Teitelbaum Aaron M.,Liu Pingrong,Chan Tom S.

Funder

Boehringer Ingelheim International GmbH

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-021-01111-9.pdf

Reference18 articles.

1. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 2001;158(9):1367–77.

2. Hu N-W, Ondrejcak T, Rowan MJ. Glutamate receptors in preclinical research on Alzheimer’s disease: update on recent advances. Pharmacol Biochem Behav. 2012;100(4):855–62.

3. Hashimoto K. Glycine transport inhibitors for the treatment of schizophrenia. Open Med Chem J. 2010;4:10–9.

4. Lin CH, Lane HY, Tsai GE. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav. 2012;100(4):665–77.

5. Balu DT. The NMDA receptor and schizophrenia: from pathophysiology to treatment. Adv Pharmacol (San Diego, Calif). 2016;76:351–82.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carbon 14 synthesis of glycine transporter 1 inhibitor Iclepertin (BI 425809) and its major metabolites;Journal of Labelled Compounds and Radiopharmaceuticals;2023-06-29

2. Characterization of Divergent Metabolic Pathways in Elucidating an Unexpected, Slow-Forming, and Long Half-Life Major Metabolite of Iclepertin;Pharmaceutical Research;2023-06-06

3. Design, conduct, and interpretation of human mass balance studies and strategies for assessing metabolites-in-safety testing (MIST) in drug development;Overcoming Obstacles in Drug Discovery and Development;2023

4. Correction to: The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [14C]‑BI 425809 in Healthy Males;Clinical Drug Investigation;2022-03-14